Retatrutide is producing bigger weight-loss numbers than Tirzepatide in clinical trials, so it is easy to assume it is automatically the better medication. The reality is more complicated. One is currently licensed and available in the UK. The other is still working through the regulatory process. Understanding that difference matters more than comparing percentages alone.
Tirzepatide (sold as Mounjaro for diabetes, Zepbound for weight loss in the US) is MHRA approved and can be legally prescribed in the UK today. It works on two receptors, GLP-1 and GIP.
Retatrutide adds a third receptor, glucagon, and has shown stronger results in trials so far. But as of July 2026, it is not approved anywhere in the world, still in Phase 3 trials, and cannot be routinely or legally prescribed in the UK. Realistic timelines put UK availability at 2027 to 2028 at the earliest.
For most people reading this today, Tirzepatide is currently the licensed option available following assessment by a qualified prescriber. This article explains both honestly, as education, not as promotion of either medication.
Considering medical weight management?
Tell me a little about your goals and I will talk you through the options that are actually licensed and available to you today.
If I do not think medication is the right route for you, I will tell you.
Message Georgina on WhatsAppBoth medications come from the same manufacturer and the same underlying science, the incretin pathway, so the comparison is a natural one. But most articles online either oversell Retatrutide as if it is already available, or undersell Tirzepatide as if it is the "old" option now that something newer exists.
Neither is accurate. I am Georgina Sookias, a Clinical Aesthetician trained to Ofqual Level 4 and 5, based in Fulham SW6. Here is the honest science, and the honest regulatory picture, without the hype.
Tap either card for the full clinical detail on the mechanism and the published trial data.
Tirzepatide is a dual agonist, activating both the GLP-1 and GIP receptors.
GLP-1 (glucagon-like peptide-1) works mainly in the brain and gut, slowing digestion and signalling fullness, which reduces how much you eat. GIP (glucose-dependent insulinotropic polypeptide) works alongside it, improving insulin sensitivity and adding to the appetite-regulating effect.
In the SURMOUNT-1 Phase 3 trial, published in the New England Journal of Medicine, participants achieved average weight reductions of up to 22.5% at the highest dose over 72 weeks, compared with 2.4% on placebo. Around 96% of participants on the higher doses achieved at least 5% weight loss.
Tirzepatide received FDA approval in 2022 and MHRA approval shortly after, and is available on private prescription in the UK today, subject to clinical assessment.
Retatrutide adds a third receptor, glucagon, on top of GLP-1 and GIP, which is why it is often called a "triple agonist".
The addition of the glucagon receptor is the key mechanical difference. Where GLP-1 and GIP mainly work by reducing appetite and improving insulin response, glucagon receptor activation is thought to have a more direct effect on the liver and on energy expenditure, potentially supporting fat metabolism even during a calorie deficit.
In Phase 2 trials, participants achieved an average of 24.2% weight loss at 48 weeks, the highest recorded for this drug class at the time. More recent Phase 3 data (TRIUMPH-1, reported May 2026) showed an average of 28.3% weight loss at 80 weeks in a trial of over 2,300 patients, with some patients on higher doses losing 30% or more of their body weight.
These are genuinely striking results. They are also, importantly, trial results, not a marketed, generally available medication.
This is the entire reason people search this comparison, so it deserves its own explanation. The first two receptors mainly turn down your appetite. The third one may turn up your metabolism.
Two receptors
Three receptors
Glucagon is the receptor unique to Retatrutide here. It is thought to act on the liver and energy expenditure, not just appetite.
Want to understand your options honestly?
The science is genuinely interesting, but what matters is what is safe and available for you. Message me and I will explain the licensed options plainly.
Advice first, never a hard sell.
Message Georgina on WhatsAppThe regulatory journey for any new medication runs from research through to prescription. Seeing where each medication sits makes the real difference clear.
It is not that Retatrutide is a lesser option, it is simply earlier in a process that Tirzepatide has already completed.
Not sure what is actually available to you now?
Tell me your situation and I will explain what is licensed and appropriate today, rather than what is still in trials.
If a medication is not right for you, I will say so.
Message Georgina on WhatsAppThis is not about which one "wins." Both are prescription medications intended for specific groups, not a general lifestyle product.
Neither medication is appropriate as a casual, self-directed choice. Both require proper clinical assessment first.
This is a general guide based on published trial data, not a personal prediction. Individual results vary significantly and depend on proper clinical assessment and monitoring.
This is the part most comparison articles gloss over, so here it is in full.
Tirzepatide
Retatrutide
If you see Retatrutide being sold or offered as a straightforward weight-loss treatment anywhere, that is a signal to be cautious, not a sign it is now available.
Thinking about weight management the safe way?
If you are weighing up options, message me first. I would rather guide you to a licensed, monitored route than see you risk an unregulated source.
If I do not think you are a good candidate, I will tell you.
Message Georgina on WhatsAppThis is not unusual or a red flag, it is simply how medicine regulation works.
None of this means Retatrutide will not eventually be approved, the trial data so far looks genuinely promising. It just means "promising trial results" and "ready for the public" are two different things, and conflating them is exactly how people end up taking real risks with unregulated sources.
If your goal is to lose weight safely under proper medical supervision, I would rather you choose a licensed treatment today than chase an unlicensed medication from an unregulated source. A few extra percentage points of trial weight loss are not worth the safety and quality risks of sourcing something outside proper medical channels.
If you want to go deeper on this, my Retatrutide UK guide covers the current UK picture in more detail, and my Mounjaro vs Retatrutide comparison looks at how the licensed option compares.
If a headline weight-loss percentage is what brought you to this article, it is worth remembering that the medication actually available to you today is Tirzepatide, not Retatrutide, regardless of which one performs better in trials.
“Retatrutide is basically available if you know where to look.”
Grey market and research peptide sources exist, but they are not a legal or safe route to access an unlicensed medicine. Quality, dosing accuracy and safety are not guaranteed.
“Tirzepatide is the outdated option now that Retatrutide exists.”
No. Tirzepatide is a licensed, well studied, currently available medication with a strong safety and efficacy record. Retatrutide showing stronger trial numbers does not make Tirzepatide obsolete, particularly since one of them you can actually access safely today.
“Higher weight loss percentages in trials mean it is definitely the better choice for everyone.”
Trial averages do not predict individual results, and a medication’s suitability depends on your overall health, other conditions and a proper clinical assessment, not just a headline statistic.
Question not answered here?
Send it over. I would much rather answer honestly than have you spend money on the wrong treatment.
If the honest answer is that you do not need this, I will say so.
Message Georgina on WhatsAppA weight management consultation with a qualified prescriber will focus on what is actually licensed and appropriate for you, following proper assessment. Honest advice, never a hard sell. You can also read how we think about peptides more broadly in the peptide therapy guide.
South Park Studios, 88 Peterborough Road, Fulham SW6 3HH
This article is for informational and educational purposes only and does not constitute medical advice, nor an offer to supply any specific medication. Retatrutide is not licensed or available in the UK as of July 2026. Weight management medication is prescribed only following individual clinical assessment by a qualified prescriber. Individual results may vary and are not guaranteed.